Latest Breaking News On - Prenetics group limited - Page 1 : comparemela.com

- Highly sensitive ColoClear test offers convenient screening method that can be completed with simple stool sample at-home, providing an easy alternative to Colonoscopy - Test sensitivity of 96% in colorectal cancer and 64% in advanced adenoma detection in clinical studies - ColoClear is the only cancer screening test approved by the National Medical Products Administration (NMPA) HONG KONG, June 9, 2022 /PRNewswire/ Prenetics Group Limited (Nasdaq: PRE), a global leader in genomic and diagnostic testing, has introduced a novel, non-invasive, at-home screening test - ColoClear by Circle (ColoClear), for detecting early signs of colorectal cancer. Colorectal cancer is the second most common cancer in Hong Kong, accounting for 15.8% of total new cancers in 2019[1]. Combining advanced stool DNA technology with a faecal immunochemical test (FIT), the revolutionary test is the first line of defense against one of the most preventable cancers, which can be treated in 90% of cases when dete

South africaUnited statesHong kongUnited kingdomDanny yeungAlex fongYeqing zhuStock exchange of hong kongPrenetics group limited nasdaqNational medical products administrationHorizon healthPrenetics groupPrenetics group limitedNew horizon healthNegative predictive valueGiven coloclear